The population of interest was men at risk of developing prostate cancer, the interventions reviewed were novel biomarkers and MRI-guided biopsy techniques as prostate cancer diagnostic tools, the alternatives against which the interventions were compared were standard diagnostic tools such as the PSA test, TRUS-guided biopsy, or no intervention, and the outcome considered was the cost-effectiveness of these interventions in comparison with each other. This evidence concerns the gene KLK3 and Familial prostate cancer.